Bolt Capital Lease Obligations from 2010 to 2024
| BOLT Stock | USD 0.63 0.03 5.00% |
Capital Lease Obligations | First Reported 2010-12-31 | Previous Quarter 20.2 M | Current Value 16.2 M | Quarterly Volatility 9.5 M |
Check Bolt Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bolt Biotherapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 6.5 M, Interest Income of 6.5 M or Depreciation And Amortization of 2.5 M, as well as many indicators such as Price To Sales Ratio of 5.11, Dividend Yield of 0.0 or PTB Ratio of 0.39. Bolt financial statements analysis is a perfect complement when working with Bolt Biotherapeutics Valuation or Volatility modules.
Bolt | Capital Lease Obligations |
Latest Bolt Biotherapeutics' Capital Lease Obligations Growth Pattern
Below is the plot of the Capital Lease Obligations of Bolt Biotherapeutics over the last few years. Bolt Biotherapeutics capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Bolt Biotherapeutics asset purchases. For example, Bolt Biotherapeutics can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Bolt Biotherapeutics control over an asset for a big portion of its life. It is the total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee. Bolt Biotherapeutics' Capital Lease Obligations historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bolt Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
| Capital Lease Obligations | 10 Years Trend |
|
Capital Lease Obligations |
| Timeline |
Bolt Capital Lease Obligations Regression Statistics
| Arithmetic Mean | 6,986,197 | |
| Geometric Mean | 444,550 | |
| Coefficient Of Variation | 136.07 | |
| Mean Deviation | 8,335,436 | |
| Median | 40,000 | |
| Standard Deviation | 9,506,276 | |
| Sample Variance | 90.4T | |
| Range | 24.3M | |
| R-Value | 0.84 | |
| Mean Square Error | 29.5T | |
| R-Squared | 0.70 | |
| Significance | 0.0001 | |
| Slope | 1,775,042 | |
| Total Sum of Squares | 1265.2T |
Bolt Capital Lease Obligations History
About Bolt Biotherapeutics Financial Statements
Bolt Biotherapeutics shareholders use historical fundamental indicators, such as Capital Lease Obligations, to determine how well the company is positioned to perform in the future. Although Bolt Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Bolt Biotherapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Bolt Biotherapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Capital Lease Obligations | 20.2 M | 16.2 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Bolt Stock Analysis
When running Bolt Biotherapeutics' price analysis, check to measure Bolt Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bolt Biotherapeutics is operating at the current time. Most of Bolt Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bolt Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bolt Biotherapeutics' price. Additionally, you may evaluate how the addition of Bolt Biotherapeutics to your portfolios can decrease your overall portfolio volatility.